anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Childhood cancer survivors are at risk of developing primary recurrences and new second cancers. Experiencing a recurrence and/or second cancer can be highly distressing for survivors and families. We aimed to understand the psychological impacts of experiencing a recurrence or second cancer and how this potentially influences survivors' engagement with survivorship care.
METHODS: We invited childhood cancer survivors or their parents if survivors were ≤16 years of age from 11 tertiary pediatric oncology hospitals across Australia and New Zealand to complete interviews. We conducted a thematic analysis facilitated by NVivo12.
RESULTS: We interviewed 21 participants of whom 16 had experienced a recurrence, 3 had a second cancer, and 2 had both a recurrence and second cancer. Participants reported that a recurrence/second cancer was a stressful sudden disruption to life, accompanied by strong feelings of uncertainty. Participants tended to be less aware of their second cancer risk than recurrence risk. Some participants reported feelings of anxiousness and despair, describing varying responses such as gratitude or avoidance. Participants shared that the fear of cancer recurrence either motivated them to adopt protective health behaviors or to avoid information and disengage from survivorship care.
SIGNIFICANCE OF RESULTS: Some survivors and their parents have a poor understanding and expressed reluctance to receive information about their risk of second cancer and other treatment-related late effects. Improving the delivery of information about late effects to families may improve their engagement with survivorship care and surveillance, although care must be taken to balance information provision and survivors' anxieties about their future health.
Provided is an antibody that specifically binds human a?ßß and blocks binding of TGFp peptide to a?ß8, wherein the antibody binds to the specificity determining loop (SDL) of human ß8. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the a1 helix of human ß8, or the a1 helix of human ß8. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-a?ßß antibodies or antigen-binding molecules thereof.
The present invention provides a device for controlled release of molecules. The device is particularly suitable for controlled release of therapeutic drugs to a patient. The device includes a housing with an opening for release of the molecules from the housing. The housing also comprises a reservoir for containing the molecules, in particular therapeutic drugs. The reservoir is arranged in the housing to allow release of the molecules through the opening. The device also comprises at least one thermoswitchable membrane and at least one heating element for at least partially heating the membrane. The device is configured for modulating the release of the molecules at the opening by heating the membrane, using the heating element. Optionally, the device further comprises a pressure element for providing pressurized release of the molecules from the device. In this way, the drug can be delivered to a patient in a pulsatile fashion. The present invention also provides a method for modulating the release of molecules, using such a device.
Blood will be drawn on day 15 of the next cycle after enrollment and the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.
PURPOSE: Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking.
EXPERIMENTAL DESIGN: Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response.
RESULTS: The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response.
CONCLUSIONS: Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.
Multiple sclerosis (MS) is a chronic autoimmune neurological disorder characterized by central nervous system demyelination, leading to various neurological impairments. While the primary focus of research and clinical management has centered on the neurological aspects of MS, emerging evidence suggests a complex interplay between MS and renal disease. This narrative review endeavors to elucidate the intriguing association between MS and renal disease, providing a comprehensive overview of the current knowledge on this topic. Our review begins by outlining the pathophysiology of MS and the diverse mechanisms contributing to its progression. We then delve into renal disease, categorizing the various types and their clinical presentations. This review focuses on exploring the intricate relationship between these seemingly distinct conditions. We analyze existing literature to uncover shared risk factors, potential pathophysiological links, and the impact of MS on renal function. Furthermore, we discuss the clinical presentation and diagnostic challenges in identifying renal disease in MS patients. Importantly, we examine available treatment options and their efficacy in managing renal complications in this unique patient population. The consequences of renal disease on the overall quality of life (QOL) for individuals living with MS are also examined, shedding light on the multifaceted burden of these coexisting conditions.
Although there have been no carcinogenesis studies with levalbuterol HCl, racemic albuterol sulfate has been evaluated for its carcinogenic potential.

In a 2-year study in Sprague-Dawley rats, dietary administration of racemic albuterol sulfate resulted in a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at doses of 2 mg/kg/day and greater (approximately 4 times the MRHDID of levalbuterol HCl for adults and approximately 5 times the MRHDID of levalbuterol HCl for children on a mg/m2 basis). In an 18-month study in CD-1 mice and a 22-month study in the golden hamster, dietary administration of racemic albuterol sulfate showed no evidence of tumorigenicity. Dietary doses in CD-1 mice were up to 500 mg/kg/day (approximately 540 times the MRHDID of levalbuterol HCl for adults and approximately 630 times the MRHDID of levalbuterol HCl for children on a mg/m2 basis) and doses in the golden hamster study were up to 50 mg/kg/day (approximately 90 times the MRHDID of levalbuterol HCl for adults on a mg/m2 basis and approximately 105 times the MRHDID of levalbuterol HCl for children on a mg/m2 basis).

Levalbuterol HCl was not mutagenic in the Ames test or the CHO/HPRT Mammalian Forward Gene Mutation Assay. Levalbuterol HCl was not clastogenic in the in vivo micronucleus test in mouse bone marrow. Racemic albuterol sulfate was not clastogenic in an in vitro chromosomal aberration assay in CHO cell cultures.

No fertility studies have been conducted with levalbuterol hydrochloride. Reproduction studies in rats using racemic albuterol sulfate demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg/day (approximately 108 times the maximum recommended daily inhalation dose of levalbuterol HCl for adults on a mg/m2 basis).
We studied whether the two-plate tension band configuration is more prone for intraarticular deformations than the single plate application used for coronal plane deformities (CPD). The study was based on radiological chart review (retrospective cross-sectional) of records of children [15 patients (30 plates) with limb length discrepancies (LLD) and 20 patients (36 plates) with CPD]. Interscrew angle, slope angle, and roof angle were compared in the initial postoperative and final radiographs to determine changes of tibial morphology. The mean patient age and follow up for the LLD and CPD groups respectively were 6.5 years, 39.8 months and 8.1 years, 15.5 months respectively. The interscrew angles widened between initial and final radiographs in the CPD group and for both sides in the LLD group. The initial and final slope angles were not significantly different in both LLD and CPD groups. Similar trend was observed for roof angle in either group. In the intergroup comparisons between LLD and CPD group, the slope angle of medial/lateral operated side in LLD group versus that of the operated side in CPD group matched statistically in the final radiographs. Similarly, the final roof angle in LLD and CPD groups was statistically similar. No significant intraarticular morphological change was demonstrated following tension band plating epiphysiodesis of the proximal tibia for our series involving young children. It was observed neither with the two-plate configuration used for limb length decelerations nor with the single plate application for coronal plane corrections.
BACKGROUND: Autoimmune diseases often coexist; however, the concomitant occurrence of systemic lupus erythematosus (SLE) and primary biliary cirrhosis (PBC) is rare. Therefore, this study aims to provide a comprehensive summary of evidence regarding the co-occurrence of SLE and PBC.
METHODS: PubMed, Web of Science, ScienceDirect , and Google Scholar databases were systematically and comprehensively searched for records published up to February 2024. Full-text articles that aligned with the study's aim were included, while those published in languages other than English and those designed as case reports, reviews, conference abstracts, or editorials were excluded. Statistical analyses were performed using Comprehensive Meta-Analysis software, and methodological quality was assessed using the Newcastle-Ottawa Scale.
RESULTS: Only 14 studies that met the inclusion criteria with 3944 PBC and 9414 SLE patients were included for review and analysis. Pooled data analysis revealed that approximately 1.1% of SLE patients have concomitant PBC (range: 0.02-7.5%), while around 2.7% of PBC patients concurrently have SLE (range: 1.3-7.5%). Furthermore, qualitative data analysis indicated that the prevalence of PBC in SLE patients presenting with hepatic dysfunction or abnormal liver enzymes ranges from 2 to 7.5%.
CONCLUSION: Although the concomitant occurrence of SLE and PBC is rare, the small proportion of patients where these diseases coexist warrants close monitoring by clinicians. This underscores the importance of surveillance to prevent their co-occurrence.
PURPOSE:To obtain an antiviral agent, capable of manifesting excellent effects and safety, containing only a grape pigment or having enhanced antiviral properties by further adding an extracted essence of Rosa roxburghii Tratt. thereto and a feed or a functional food using the same. CONSTITUTION:This antiviral agent contains a grape pigment obtained by extracting a grape pericarp or fruit, etc. This feed or functional feed is obtained by using the grape pigment. When the grape pigment is used as the feed or functional food, the concentration of the grape pigment is 0.01-5%, preferably 0.05-3%. Antiviral activities of the antiviral agent can be enhanced by using an extract of Rosa roxburghii Tratt. without manifesting the antiviral actions itself in addition to the grape pigment. The blending ratio thereof is preferably basically nearly the equal amounts.
Antibody-mediated complement-dependent cytotoxicity (CDC) on malignant cells is regulated by several complement control proteins, including the inhibitory complement factor H (fH). fH consists of 20 short consensus repeat elements (SCRs) with specific functional domains. Previous research revealed that the fH-derived SCRs 19-20 (SCR1920) can displace full-length fH on the surface of chronic lymphocytic leukemia (CLL) cells, which sensitizes CLL cells for e.g. CD20-targeting therapeutic monoclonal antibody (mAb) induced CDC. Therefore, we constructed lentiviral vectors for the generation of cell lines that stably produce mAb-SCR-fusion variants starting from the clinically approved parental mAbs rituximab, obinutuzumab and ofatumumab, respectively. Flow-cytometry revealed that the modification of the mAbs by the SCRs does not impair the binding to CD20. Increased in vitro lysis potency compared to their parental mAbs was corroborated by showing specific and dose dependent target cell elimination by CDC when compared to their parental mAbs. Lysis of CLL cells was not affected by the depletion of NK cells, suggesting that antibody-dependent cellular cytotoxicity plays a minor role in this context. Overall, this study emphasizes the crucial role of CDC in the elimination of CLL cells by mAbs and introduces a novel approach for enhancing CDC by directly fusing fH SCR1920 with mAbs.
Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
Methods for diagnosing, treating, and reducing the risk of developing sepsis, by measuring or targeting interleukin 3 (IL-3). The present invention is based, at least in part, on the discovery that the cytokine interleukin (IL)-3 potentiates inflammation in sepsis. Thus, described herein are methods for diagnosing sepsis, severe sepsis, or septic shock in a subject. Also provided herein are methods for predicting risk of mortality in a subject with sepsis, severe sepsis, or septic shock. Also provided herein are methods for monitoring the condition or risk of mortality in a subject with sepsis, severe sepsis, or septic shock. In addition, provided herein are methods for determining the efficacy of a treatment for sepsis, severe sepsis, or septic shock.
PCT No. PCT/EP96/02407 Sec. 371 Date Feb. 25, 1998 Sec. 102(e) Date Feb. 25, 1998 PCT Filed May 31, 1996 PCT Pub. No. WO96/38170 PCT Pub. Date Dec. 5, 1996The invention relates to a composition to improve digestibility and utilisation of nutrients, comprising one or more acid stable lipases and/or one or more acid stable amylases. Both the lipase and the amylase may be of fungal origin. The lipase preferably originates from Rhizopus arrhizus or Rhizopus javanicus and the amylase from Aspergillus niger. The composition is for example a pharmaceutical composition for use in the treatment of exocrine pancreas insufficiency which may be the result of or a side-effect of acquired chronic pancreatitis, alcoholism, cystic fibrosis or pancreatic carcinomas.
Participants will first receive a Placebo for 28 days. After a washout period of 14 days, they will then receive a 30 mg Pioglitazone tablet once daily for 28 days.
Hemorrhagic cystitis may develop in patients treated with cyclophosphamide. Rarely, this condition can be severe and even fatal. Fibrosis of the urinary bladder, sometimes extensive, also may develop with or without accompanying cystitis. Atypical urinary bladder epithelial cells may appear in the urine. These adverse effects appear to depend on the dose of cyclophosphamide and the duration of therapy. Such bladder injury is thought to be due to cyclophosphamide metabolites excreted in the urine. Forced fluid intake helps to assure an ample output of urine, necessitates frequent voiding, and reduces the time the drug remains in the bladder. This helps to prevent cystitis. Hematuria usually resolves in a few days after cyclophosphamide treatment is stopped, but it may persist. Medical and/or surgical supportive treatment may be required, rarely, to treat protracted cases of severe hemorrhagic cystitis. It is usually necessary to discontinue cyclophosphamide therapy in instances of severe hemorrhagic cystitis.
Group Dex received 0.5 mcg/kg of dexmedetomidine IV for 10 minutes, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
The invention discloses semen cassiae oral liquid capable of relaxing bowels and lubricating intestines. The oral liquid is used for treating constipation caused by gastrointestinal heat, intestinal dry and body fluid deficiency. The oral liquid comprises, by weight, 10-50 parts of semen cassiae, 10-20 parts of scutellaria baicalensis, 10-20 parts of root of rehmannia, 10-20 parts of semen plantaginis, 10-20 parts of bighead atractylodes rhizome, 10-20 parts of radix scrophulariae, 10-20 parts of fructus aurantii, 10-20 parts of lotus leaves, 10-20 parts of fructus cannabis, 10-20 parts of gynostemma pentaphylla, 10-20 parts of mulberries, 10-20 parts of cape jasmine, 10-20 parts of curcuma aromatica, 10-20 parts of angelica sinensis, 10-20 parts of pericarpium citri reticulatae, 10-20 parts of indigo naturalis and 10-20 parts of mangnolia officinalis. The semen cassiae has the functions of clearing liver, improving vision, relaxing bowels, lubricating intestines, reducing fat and losing weight. Besides saccharides, protein and fat, the oral liquid further contains steroids, chrysophanic acid, rheum emodin and microelements, such as Fe, Zn, Mn, Cu, Ni, Co and Mo, which are essential to human bodies. The semen cassiae tastes bitter, and the taste of the semen cassiae is not easy for people to accept. By means of the oral liquid, the functions of reducing fat, losing weight, relaxing bowels and lubricating intestines are well achieved.
OBJECTIVE: To investigate the gender gap in the context of stone-related surgery within an Israeli population.
METHODS: We conducted a retrospective cohort study using administrative databases from Clalit Health Services to identify adults aged 18 and above who had their initial surgical treatment for upper tract urolithiasis. We employed descriptive statistics to outline the baseline patient characteristics, and the Cochran-Armitage test for trend was utilized to analyze surgical trends.
RESULTS: Between 2003 and 2020, a total of 36,624 adult patients underwent surgical treatment for upper tract urinary stones. The mean age of patients was 55.01 years (standard deviation (SD) 16.6) for ureteroscopy (URS), 55.05 years (SD 15.1) for percutaneous nephrolithotripsy (PCNL), and 51.07 years (SD 15.1) for shockwave lithotripsy (SWL). When considering the distribution of procedures by gender, males accounted for 69.5% of URS cases, 58.3% of PCNL cases, and 70.6% of SWL cases, whereas females represented 30.5%, 41.7%, and 29.4% of URS, PCNL, and SWL cases, respectively. Across all surgical modalities, the male-to-female ratio exhibited fluctuations without a consistent trend, with both increases and decreases observed. In URS, the ratio saw a modest increase from 1.967 in 2003 to 2.173 in 2020. For PCNL, the ratio initially increased from 2.361 in 2003 to 2.549 in 2014, followed by subsequent fluctuations, but an overarching trend was not apparent. In contrast, for SWL, the ratio decreased from 2.15 in 2003 to 1.32 in 2020, with varying changes in between.
CONCLUSION: This study highlights the dynamic nature of gender gap in stone-related surgery outcomes. While the male-to-female ratio exhibited fluctuations over a 17-year period, no consistent trend emerged. The absence of a clear trend underscores the complex and multifaceted factors influencing the gender gap in urolithiasis.
Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Participants will receive a single oral dose of rilematovir (Treatment A) in Treatment Period 1, followed by a single oral dose of ciclosporin (Treatment B) in Treatment Period 2 and then single oral dose of ciclosporin plus single oral dose of rilematovir (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.